Methylation of the ER-alpha Promoter Is Influenced by its Ligand Estrogen in Osteosarcoma Cells SAOS-2 In Vitro.

Background/Aim: The aggressive fast-growing osteosarcoma is the most common primary malignant bone tumor. The relevance of estrogen as a key player in bone metabolism and bone tumor is well-known. At the molecular level, estrogen activates the estrogen receptor alpha (ER alpha) as a natural ligand of this receptor. ER alpha acts as a transcription factor by binding to the "estrogen response element" (ERE) and regulates the expression of a various number of genes. Epigenetic processes, e.g. the methylation of the "cytosine-phosphatidyl-guanine (CpG) islands" can change the transcription of target genes and subsequently the protein expression. As DNA methylation is generally associated with gene transcription repression, up until now little is known about the ERa methylation in osteosarcoma cells. The aim of the present pilot study was to evaluate the methylation status of ERa in osteosarcoma cells SAOS-2 and MG 63 after stimulation with estrogen. Materials and Methods: SAOS-2 and MG 63 cells were cultured in DMEM. After treatment with 10 nmol estrogen (E2) for 24 h, the expression of ERa was detected by immunocytochemistry (ICC). As controls we used untreated cells. Staining was evaluated semi-quantitatively by the immunoreactive score of Remmele and Stegner (IRS). To determine mRNA gene expression, extracted RNA was transcribed into c-DNA and a quantitative real-time-PCR (qRT-PCR) was carried out. The semi quantitative evaluation of the ER alpha mRNA was based on the 2(-Delta Delta ct) method using untreated cells as reference control. One microgram of each extracted genomic DNA sample was converted with bisulfite and a real-time methylation-specific PCR (rt-MSP) was performed. Results: The estrogen-stimulated SAOS-2 cells showed a significant increase of ER alpha expression. A 7-fold up-regulation of ER alpha mRNA confirmed the results of immunocytochemistry. Methylation of the ER alpha promoter was not detected in treated cells. In contrast, we identified methylation of the ER alpha promoters in untreated cells. The staining of MG 63 cells showed a weak gain of ER alpha expression in the stimulated cells, as well as a weak increase of the ER-alpha mRNA (2-fold). Methylation of the ER alpha promoters was not detectable in either treated or untreated cells. Conclusion: The methylation status of ER alpha in osteosarcoma cells is affected by estrogen. These findings indicate that epigenetic changes of genomic DNA regulate ER alpha synthesis. Taken together, our results suggest that SAOS-2 cells can be an interesting model for further investigating ER alpha synthesis. In addition, the evaluation of ER alpha methylation in osteosarcoma specimens is in progress.